drugset / Trial / NCT00751478

Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)

NCT00751478

Phase 1/2 Completed 32 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of the study is to determine the relative pharmacodynamic effects and safety of crushed and whole ALO-01 compared to MSIR and to Placebo, and of crushed ALO-01 to whole ALO-01; to determine the relative bioavailability of plasma morphine from crushed and whole ALO-01 compared to MSIR, and from crushed ALO-01 to whole ALO-01; and to determine the relative bioavailability of plasma naltrexone and 6-β-naltrexol from crushed ALO-01 to whole ALO-01.

Timeline

Start
2007-03
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ALO-01 Unknown 120 mg Oral
Comparator Morphine Other / unclassified 120 mg Oral

Indications

No indication recorded.